Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

BP reduction during studies mmHg SBP DBP D mmHHg VALUE 170 Valsartan 165 (N= 7649) Amlodipine (N = 7596) 155 150 145 140 135 130 90 85 80 75 Baseline 1 2 3 4 6 12 18 24 30 36 42 48 54 60 66 Months CASE-J (or final visit) Atacand ® (N = 2354) Amlodipine (N= 2349)
Cardiac event (VALUE Primary endpoint) Proportion of patients with first event (%) 14 12 10 8 6 4 2 0 VALUE (Valsartan) CASE-J (Candesartan) HR = 1.03 (95% CI = 0.94–1.14) p= 0.49 0 6 12 18 24 30 36 42 48 54 60 66 Proportion of patients with first event (%) 10 8 6 4 2 0 Time (months) HR=1.01 (95% CI 0.79-1.28) p=0.969 Baseline 6 12 18 24 30 36 42 48 Valsartan-based Valsartan based regimen Amlodipine-based regimen Atacand ® -based regimen
Page 1 and 2: Comparison of Candesartan vs Amlodi
Page 3 and 4: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6: LIFE Incidence of Diabetes Mellitus
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 62 and 63: Summary IIn comparison i with i h s
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr

Comparison of Candesartan vs Amlodipine Comparison of ...

Create successful ePaper yourself

Delete template?

Save as template?